Publication:
Efficacy and safety of tenofovir alafenamide (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of tenofovir disoproxil fumarate (TDF)

Simple item page
dc.contributor.authorButi, Maria
dc.contributor.authorStepanova, Tatjana
dc.contributor.authorCelen, Mustafa K.
dc.contributor.authorFlisiak, Robert
dc.contributor.authorRyder, Stephen D.
dc.contributor.authorStreinu, Adrian Cercel
dc.contributor.authorFlaherty, John F.
dc.contributor.authorGaggar, Anu
dc.contributor.authorSuri, Vithika
dc.contributor.authorMo, Shuyuan
dc.contributor.authorSubramanian, Mani
dc.contributor.authorNurmukhametova, Elena
dc.contributor.authorZoulim, Fabien
dc.contributor.authorAndreone, Pietro
dc.contributor.authorMarcellin, Patrick
dc.contributor.buuauthorGürel, Selim
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Dahiliye Anabilim Dalı/Gastroenteroloji Bilim Dalı.tr_TR
dc.contributor.researcheridHLH-8209-2023tr_TR
dc.date.accessioned2023-09-21T06:23:30Z
dc.date.available2023-09-21T06:23:30Z
dc.date.issued2017-10
dc.descriptionBu çalışma, 20-24, Ekim 2017 tarihlerinde Washington[Amerika]’da düzenlenen 68. Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting Kongresi‘nde bildiri olarak sunulmuştur.tr_TR
dc.description.sponsorshipAmer Assoc Study Liver Disen_US
dc.description.sponsorshipGilead Sciencesen_US
dc.description.sponsorshipJohnson & Johnson Johnson & Johnson USA Janssen Biotech Incen_US
dc.description.sponsorshipAbbVieen_US
dc.description.sponsorshipRoche Holdingen_US
dc.description.sponsorshipAssemblypharmen_US
dc.description.sponsorshipContraviren_US
dc.description.sponsorshipArbutusen_US
dc.description.sponsorshipSanofien_US
dc.description.sponsorshipBristol-Myers Squibben_US
dc.description.sponsorshipMerck & Company Schering Plough Corporationen_US
dc.identifier.citationButi, M. vd. (2017). ''Efficacy and safety of tenofovir alafenamide (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of tenofovir disoproxil fumarate (TDF)''. Hepatology, 66(Supplement 1), Special Issue, 488A-488A.en_US
dc.identifier.endpage488Atr_TR
dc.identifier.issn0270-9139
dc.identifier.issn1527-3350
dc.identifier.issueSupplement 1, Special Issueen_US
dc.identifier.startpage488Atr_TR
dc.identifier.urihttps://aasldpubs.onlinelibrary.wiley.com/loi/15273350
dc.identifier.urihttp://hdl.handle.net/11452/33935
dc.identifier.volume66tr_TR
dc.identifier.wos000412089801057
dc.indexed.wosSSCIen_US
dc.indexed.wosCPCISen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.collaborationYurt dışıtr_TR
dc.relation.collaborationYurt dışıtr_TR
dc.relation.journalHepatologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararasıtr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGastroenterology & hepatologyen_US
dc.subject.wosGastroenterology & hepatologyen_US
dc.titleEfficacy and safety of tenofovir alafenamide (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of tenofovir disoproxil fumarate (TDF)en_US
dc.typeMeeting Abstract
dc.wos.quartileQ1en_US
dspace.entity.typePublication

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus